New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma

scientific article published on 31 July 2019

New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3390/CANCERS11081086
P932PMC publication ID6721310
P698PubMed publication ID31370258

P50authorGiuseppe ToffoliQ54252459
Michele Dal BoQ42703041
P2093author name stringLorena Baboci
Federica Di Cintio
Davide Busato
Monica Mossenta
P2860cites workColchicine and 2-methoxyestradiol Inhibit Human AngiogenesisQ46442700
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibitionQ46944486
Recent developments of c-Met as a therapeutic target in hepatocellular carcinomaQ48140297
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialQ50046367
Regorafenib for treatment of hepatocellular carcinomaQ50069191
Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.Q53179931
Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicalsQ53359901
Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.Q54362470
Brucine, an indole alkaloid from Strychnos nux-vomica attenuates VEGF-induced angiogenesis via inhibiting VEGFR2 signaling pathway in vitro and in vivoQ54454388
Angiopoietin-2 TIEs Up Macrophages in Tumor AngiogenesisQ54589611
Tyrosine Kinase Inhibitor PTK/ZK Enhances the Antitumor Effects of Interferon-α/5-Fluorouracil Therapy for Hepatocellular Carcinoma CellsQ54652252
Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1Q24323317
Control of the immune response by pro-angiogenic factorsQ27004733
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.Q55190117
Cabozantinib in Patients with Advanced and Progressing Hepatocellular CarcinomaQ56373211
The Role of Angiogenesis in Hepatocellular CarcinomaQ57053754
Molecular therapies and precision medicine for hepatocellular carcinomaQ57143856
Hepatocellular carcinomaQ57756376
Apatinib targets both tumor and endothelial cells in hepatocellular carcinomaQ58779802
Emerging therapies in advanced hepatocellular carcinomaQ58802297
Targeting the IDO1 pathway in cancer: from bench to bedsideQ58803138
Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and PharmacodynamicsQ58814455
The alpha-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growthQ64450133
Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic miceQ73091505
Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinaseQ73838278
Enhancing effects of green tea components on the antitumor activity of adriamycin against M5076 ovarian sarcomaQ77938248
Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergyQ79609692
Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytesQ84461047
The parallel lives of angiogenesis and immunosuppression: cancer and other talesQ84975992
Novel immunotherapeutic approaches for hepatocellular carcinoma treatmentQ92589900
Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude miceQ39748905
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).Q39838865
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft modelsQ40198053
ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cellsQ40342967
Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.Q40427748
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.Q40479307
trans-3,4,5'-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cellsQ40527959
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.Q40657525
Curcumin is an in vivo inhibitor of angiogenesisQ40884040
Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell linesQ41189104
Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterizationQ41992834
Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityQ42775676
Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectivesQ42871162
Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma.Q42971014
Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions.Q43041612
Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapesQ43693027
Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitorsQ43907793
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disordersQ44150789
Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast materialQ44159250
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.Q44285254
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumorsQ44649604
An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.Q44679244
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression.Q46017879
Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapyQ46079896
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumoursQ46119505
ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograftQ46310541
RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancerQ27657185
Sorafenib in advanced hepatocellular carcinomaQ27861075
Myeloid-derived suppressor cells as regulators of the immune systemQ28131637
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerQ28251373
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administrationQ28378001
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialQ29547903
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisQ29617585
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxiaQ30399006
Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatmentQ30736567
Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activityQ31153818
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitorQ33241590
Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cellsQ33258782
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation studyQ33441170
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumorsQ33765767
Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography.Q33798661
Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular CarcinomaQ33898877
Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply.Q33920350
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancerQ34031748
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?Q34088265
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverageQ34144848
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.Q34166741
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.Q34347917
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapyQ34354300
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.Q34398347
Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.Q34506608
BAY 43-9006 inhibition of oncogenic RET mutantsQ34565246
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinomaQ34566598
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activityQ34580980
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.Q34634826
Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast groQ34752683
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinaseQ34819659
Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinomaQ34842280
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumorsQ35064894
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapiesQ35207756
Advances in kinase targeting: current clinical use and clinical trialsQ35329430
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myelomaQ35540030
Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing PeptibodyQ35604097
Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot studyQ35797957
Genistein, a dietary-derived inhibitor of in vitro angiogenesisQ36192742
Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.Q36301943
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapyQ36378276
Chemotherapy and dietary phytochemical agentsQ36516033
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancerQ36697575
Pazopanib: a novel multitargeted tyrosine kinase inhibitorQ36731530
Molecular basis for sunitinib efficacy and future clinical developmentQ36906667
Vascular changes in hepatocellular carcinomaQ37165456
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinomaQ37285551
GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cellsQ37620336
Tumor angiogenesis: molecular pathways and therapeutic targetsQ37953773
Bevacizumab: a review of its use in advanced cancerQ38260176
FDA-approved small-molecule kinase inhibitors.Q38480289
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinomaQ38728953
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialQ38785510
Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistanceQ38948090
Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.Q39013030
Tumour-associated macrophages as treatment targets in oncology.Q39100693
PTK787/ZK222584 Combined with Interferon Alpha and 5-Fluorouracil Synergistically Inhibits VEGF Signaling Pathway in Hepatocellular CarcinomaQ39178798
Vandetanib, an Inhibitor of VEGF Receptor-2 and EGF Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in MiceQ39345406
EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenibQ39362619
Microenvironmental regulation of tumour angiogenesisQ39433862
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor GrowthQ39472261
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.Q39507131
YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity in vitro and in vivoQ39569400
Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion.Q39582827
A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid TumorsQ39640343
ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.Q39702478
The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.Q39747642
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue8
P577publication date2019-07-31
P13046publication type of scholarly workreview articleQ7318358
P1433published inCancersQ27722963
P1476titleNew Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma
P478volume11

Reverse relations

cites work (P2860)
Q90403441Angiopoietin-2 induces angiogenesis via exosomes in human hepatocellular carcinoma
Q93173616LOXL2 upregulates hypoxia‑inducible factor‑1α signaling through Snail‑FBP1 axis in hepatocellular carcinoma cells
Q93167449Programmable Synthetic Protein Circuits for the Identification and Suppression of Hepatocellular Carcinoma
Q89697165Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles

Search more.